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Bone is constantly controlled by a balance between osteoblastic bone formation 
and osteoclastic bone resorption. Liquiritigenin is a plant-derived flavonoid and has 
various pharmacological effects, such as anti-oxidative, anti-tumor, and 
anti-inflammatory effects. Here, we show that liquiritigenin has dual effects on the 
proliferation of bone cells, regarding the promotion of osteoblast differentiation and the 
inhibition of osteoclast differentiation. Liquiritigenin-treated murine osteoblastic 
MC3T3-E1 cells showed an increased alkaline phosphatase activity and enhanced 
phosphorylation of Smad1/5 compared to untreated cells. Moreover, liquiritigenin 
inhibited osteoclast differentiation, its bone-resorption activity through slightly 
decreased the phosphorylation of extracellular signal-regulated kinase, c-Jun N-terminal 
kinase, and inhibitor of nuclear factor kappa B-α; however, the phosphorylation of Akt 
and p-38 slightly increased in bone marrow-derived osteoclasts. The expression levels 
of the osteoclast marker proteins nuclear factor of activated T-cells cytoplasmic-1, Src, 
and cathepsin K diminished. These results suggest that liquiritigenin may be useful as a 
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Introduction 
Bone is constantly remodeled by a controlled balance between bone formation by 
osteoblasts (OBLs) and bone resorption by osteoclasts (OCLs). OBLs are 
mononucleated bone-forming cells that are derived from mesenchymal stem cells 
(MSCs). The differentiation of MSCs into OBLs is regulated by seven important 
signaling networks (Soltanoff et al., 2009). Among them, the transforming growth 
factor-beta (TGF-β)/bone morphogenic protein (BMP) signaling pathway facilitates the 
activation of two pathways: canonical Smad-dependent pathways and non-canonical 
Smad-independent signaling pathways, including the p38 mitogen-activated protein 
kinase pathway (MAPK) (Chen et al., 2012). Both the Smad and p38 MAPK-dependent 
pathways result in the activation of Runt-related transcription factor 2 (Runx2), which is 
a key transcription factor for OBL differentiation (Komori, 2008). Meanwhile, OCLs 
are multinucleated bone-resorbing cells that mature from hematopoietic precursors of 
monocyte/macrophage lineage (Chambers, 2000; Teitelbaum, 2000). OCL 
differentiation is regulated by two important factors, macrophage colony-stimulating 
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factor (M-CSF) and receptor activator of nuclear factor kappa-B ligand (RANKL). In 
addition, recent studies have shown that oxidative stress plays important roles in 
osteoclastogenesis (Lee et al., 2005). 
Liquiritigenin is an aglycone of liquiritin, and it is one of the flavonoids present in 
Glycyrrhiza radix. Liquiritigenin has been shown to have various pharmacological 
effects, such as anti-oxidative, anti-tumor, and anti-inflammatory effects (Kupfer et al., 
2008) (Zhou et al., 2010; Jiang et al., 2013). Moreover, liquiritigenin has been reported 
to be a plant-derived, selective estrogen receptor β agonist, indicating that it is probably 
useful for the treatment of breast cancer and osteoporosis (Mersereau et al., 2008). 
Although several studies have reported the potential utility of liquiritigenin in the 
treatment of breast cancer, there is little information about the effects of liquiritigenin 
on osteoporosis. In a previous study, liquiritigenin was shown to exert the following 
pharmacological effects: increased cell growth, increased alkaline phosphatase activity, 
promotion of collagen synthesis, and the mineralization of osteoblastic MC3T3-E1 cells 
(Choi, 2012). Further, liquiritigenin has been shown to protect MC3T3-E1 cells from 
oxidative damage induced by pharmacological inhibitors of the mitochondria (Choi et 
al., 2014).  
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Based on these findings, a strong possibility that liquiritigenin has osteogenic 
activity exists, but such an effect remain to be elucidated. In this study, the effects of 
liquiritigenin on OBL proliferation and on OCL differentiation were examined. 
 
Materials and methods 
 
2.1. Reagents 
Liquiritigenin was purchased from Wako Pure Chemicals (Osaka, Japan). M-CSF 
was purchased from Kyowa Hakko Kogyo (Tokyo, Japan). Recombinant RANKL was 
prepared as described previously (Hu et al., 2008). Antibodies (Abs) were purchased as 
follows: β-actin (Cat. No. A5060, rabbit polyclonal Ab, 1:20000; Sigma-Aldrich, St. 
Louis, MO, USA), Src (Cat. No. 05-184, mouse monoclonal Ab, 1:1000; Upstate 
Biotechnology, Lake Placid, NY, USA), and heme oxygenase (HO)-1 (rabbit polyclonal 
Ab, 1:10000; Stressgen, Ann Arbor, MI, USA). Anti-c-fms (Cat. No. sc-692, rabbit 
polyclonal Ab, 1:1000), anti-RANK (Cat. No. sc-9072, rabbit polyclonal Ab, 1:1000), 
and anti-NFATc1 (Cat. No. sc-7294, mouse monoclonal Ab, 1:1000) were purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Abs specific for 
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phospho-ERK1/2 (Cat. No. 9101S, Thr202/Tyr204, rabbit polyclonal Ab, 1:1000), 
phospho-JNK (Cat. No. 9751S, Thr183/Tyr185, rabbit polyclonal Ab, 1:1000), 
phospho-p38 (Cat. No. 9211S, Thr180/Tyr182, rabbit polyclonal Ab, 1:1000), 
phospho-inhibitor of nuclear factor kappa B alpha (IκBα) (Cat. No. 2859S, Ser32, rabbit 
polyclonal Ab, 1:1000), and phospho-Akt (Cat. No. 9271S, Ser473, rabbit polyclonal 
Ab, 1:1000) were purchased from Cell Signaling Technology (Danvers, MA, USA). 
Cathepsin K Ab was prepared as described previously (Kamiya et al., 1998). The Osteo 
Assay Plate was purchased from Corning (Corning, New York, NY, USA). All other 
reagents, including phenylmethanesulfonylfluoride (PMSF) and the protease inhibitor 
cocktail, were obtained from Sigma-Aldrich. Recombinant human bone morphogenetic 
protein-2 (rhBMP-2) was purchased from R & D systems. 
 
2.2. Cell culture 
Murine osteoblastic MC3T3-E1 cells (RBRC-RCB1126) were provided by the 
RIKEN BRC through the National Bio-Resource Project of the MEXT, Japan. 
MC3T3-E1 cells were cultured in α-minimal essential medium (α-MEM) (Wako Pure 
Chemicals, Code: 135-15175; bicarbonate buffered with L-glutamine) containing 10% 
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fetal bovine serum (FBS) with 100 U/mL penicillin and 100 µg/mL streptomycin. When 
cells were differentiated into OBLs, cells were incubated with α-MEM containing 50 
μg/mL ascorbic acid, 5 mM β-glycerolphosphate, and 1 μM dexamethasone, or 100 μM 
rhBMP-2. 
The isolation of bone marrow-derived macrophages (BMMs) was performed as 
described previously (Sakai et al., 2012). Briefly, five-week-old male C57BL/6 mice 
were obtained from CLEA Japan, Inc. (Tokyo, Japan) and handled in our facilities under 
the approved protocols of the Nagasaki University Animal Care Committee. The BMMs 
were replated in culture plates and incubated in α-MEM containing 10% FBS with 100 
U/mL penicillin and 100 µg/mL streptomycin in the presence of M-CSF (50 ng/mL) and 
RANKL (50 ng/mL) for 60 h or 72 h, until the cells differentiated into multinucleated 
mature OCLs. 
The cells were fixed with 4% paraformaldehyde and stained for tartrate-resistant 
acid phosphatase (TRAP) activity using a previously described method (Sakai et al., 
2013). TRAP-positive red-colored cells with 3 or more nuclei were considered mature 
OCLs. Murine monocytic cell line RAW-D cells were kindly provided by Prof. Toshio 
Kukita (Kyushu University, Japan) and cultured in α-MEM containing 10% FBS with 
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RANKL (50 ng/mL) (Watanabe et al., 2004). For bone resorption pit formation, BMMs 
were seeded onto Osteo Assay Plates coated with thin calcium phosphate films (Corning, 
New York, NY, USA) and incubated with M-CSF and RANKL for 5 days, until mature 
OCL resorbed the calcium phosphate film. Cells were dissolved in 5% sodium 
hypochlorite. Images of the resorption pit were taken with a reverse phase microscope 
(Olympus, Tokyo, Japan). The ratios of the resorbed areas to the total areas were 
calculated using Image J image-analysis software (http://rsbweb.nih.gov/ij/) as 
described previously (Narahara et al., 2012). 
 
2.3. Cell viability assay 
Cells seeded in 96-well cell culture plates were incubated with the Cell Counting 
Kit-8 (Dojindo, Kumamoto, Japan) for 1 h, and then the absorbance at 450 nm was 
measured with a microplate reader (Bio-Rad iMarkTM, Hercules, CA, USA). 
 
2.4. Western blot analysis 
Cells were rinsed twice with ice-cold phosphate-buffered saline (PBS), and lysed in 
a cell lysis buffer (50 mM Tris-HCl [pH 8.0], 1% Nonidet P-40, 0.5% sodium 
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deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 150 mM NaCl, 1 mM PMSF, and a 
proteinase inhibitor cocktail). The protein concentration of each sample was measured 
with BCA Protein Assay Reagent (Thermo Pierce, Rockford, IL, USA). Lysate protein 
(5 µg) was applied to each lane. After SDS-PAGE, proteins were electroblotted onto a 
polyvinylidene difluoride membrane. The blots were blocked with 3% skim milk/ Tris 
Buffered Saline with 0.1%Tween 20 (TBST) for 1 h at room temperature, probed with 
various Abs overnight at 4°C, washed, incubated with horseradish 
peroxidase-conjugated secondary Abs (anti-rabbit IgG, Cat. No. 7074, 1:2000, and 
anti-mouse IgG, Cat. No. 7076, 1:2000; Cell Signaling Technology), and finally 
detected with ECL-Plus (GE Healthcare Life Sciences, Tokyo, Japan). The 
immunoreactive bands were analyzed by LAS4000-mini (Fuji Photo Film, Tokyo, 
Japan).  
 
2.5. Statistical analysis 
All values were expressed as means ± standard deviations (SD) for 3 independent 
experiments. The data were analyzed using one-way ANOVA and differences were 






3.1. Effects of liquiritigenin on the differentiation of osteoblastic MC3T3-E1 cells 
Fig. 1A shows the structure of liquiritigenin. We first examined the effects of 
liquiritigenin on the differentiation of osteoblastic MC3T3-E1 cells under two different 
induced conditions. Firstly, upon stimulation of MC3T3-E1 cells with 
β-glycerophosphate, ascorbic acid, and dexamethasone, alkaline phosphatase staining 
analysis showed that liquiritigenin dose-dependently promoted the differentiation of 
osteoblastic MC3T3-E1 cells (Fig. 1B). Secondly, in MC3T3-E1 cells stimulated with 
BMP-2, alkaline phosphatase staining also showed that liquiritigenin dose-dependently 
increased osteoblast differentiation (Fig. 1C). These results confirm that liquiritigenin 
promotes OBL differentiation of MC3T3-E1 cells. 
 
3.2. Effects of liquiritigenin on the intracellular signaling mediating the 
differentiation of osteoblastic MC3T3-E1 cells 
Next, the effects of liquiritigenin on the intracellular signaling mediating the 
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differentiation of MC3T3-E1 cells induced by BMP-2 were investigated (Fig. 1D). The 
effects of liquiritigenin on BMP2-induced early intracellular signaling pathways, 
specifically the phosphorylation of Smad1/5 were examined by western blotting, during 
OBL differentiation of MC3T3-E1 cells. As shown in Fig. 1D, phosphorylation of 
Smad1/5 in liquiritigenin-treated cells clearly increased at 15 - 120 min compared to 
untreated cells, although the protein levels of Smad1/5 were unchanged between 
liquiritigenin-treated and untreated cells. Taken together, these findings indicate that 
liquiritigenin induces the differentiation of osteoblastic MC3T3-E1 cells through the 
Smad1/5-dependent pathway. 
 
3.3. Liquiritigenin inhibits osteoclastogenesis in vitro 
To evaluate the effects of liquiritigenin on RANKL-induced osteoclastogenesis, the 
effects of liquiritigenin on OCL differentiation of RAW-D cells with RANKL (50 
ng/mL) were investigated by TRAP staining, which is a standard method to test OCL 
formation. Liquiritigenin inhibited the formation of mononuclear and multinuclear 
OCLs derived from RAW-D cells (Fig 2A). The number of TRAP-positive, 
multinucleated OCLs after liquiritigenin treatment decreased in a dose-dependent 
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manner (Fig. 2B). The cell viability of OCLs treated with 1 - 25 µM liquiritigenin was 
indistinguishable from that of untreated cells, although the viability of cells treated with 
deltamethrin at 50 µM or 100 µM significantly decreased (Fig. 2C). 
To examine further whether similar results could also be observed in native cells, the 
effects of liquiritigenin on RANKL-induced osteoclastogenesis in BMMs were tested. 
The TRAP staining indicated that 10 and 50 µM liquiritigenin treatment decreased 
multinucleated OCL formation (Fig 2D). The number of TRAP-positive BMM-derived 
OCLs significantly decreased after liquiritigenin treatment (Fig. 2E). The viability of 
OCLs treated with 2 - 10 µM liquiritigenin was comparable to that of untreated cells; 
however, 50 - 100 µM liquiritigenin treatment slightly increased cell viability (Fig. 2F). 
These results indicate that liquiritigenin significantly inhibits the osteoclastogenesis of 
RAW-D cells and BMMs, although liquiritigenin shows different effects on cell 
viability in RAW-D cells and BMMs.  
 
 




To determine whether liquiritigenin decreases the bone-resorption activity of OCLs, 
a pit formation assay with BMM-derived OCLs was performed. Bone resorption 
activity under two different conditions was tested. In the first condition, liquiritigenin 
was added at the beginning of stimulation with RANKL (50 ng/mL) and M-CSF (30 
ng/mL) (Fig. 3A, showing a). In the second condition, liquiritigenin was added three 
days after activation, when BMMs were differentiated into active OCLs (Fig. 3A, 
showing b). 
In order to compare the resorption pit area, when untreated OCLs had moderate 
resorbing activity, the OCLs treated with liquiritigenin at the beginning exhibited 
reduced resorbing activity (Fig. 3B). Moreover, the OCLs treated with liquiritigenin 
after OCL activation also showed a reduced bone-resorption activity (Fig. 3C). These 
results indicate that liquiritigenin impairs the bone-resorption activity of OCLs. 
 
3.5. Effects of liquiritigenin on the expression levels of OCL marker proteins and 
intracellular signaling 
To examine the effects of liquiritigenin on OCLs, the expression levels of OCL 
marker proteins by western blotting were determined. As shown in Fig. 4A, although 
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the expression levels of c-fms, c-fos, and RANK were unchanged at lower 
concentrations (up to 10 µM) of liquiritigenin, they decreased at higher concentrations 
(50 - 100 µM) of liquiritigenin. However, the protein levels of NFATc1 considerably 
decreased upon 10 µM liquiritigenin treatment. Consistent with these results, the 
expression levels of Src and cathepsin K, which are transcriptionally regulated by 
NFATc1, were also found to be decreased by liquiritigenin treatment. Thus, 
liquiritigenin inhibits the expression of various OCL marker proteins. 
Therefore, the expression levels of HO-1, a phase II antioxidant cytoprotective 
enzyme against oxidative stress, were examined after liquiritigenin treatment. HO-1 
levels increased upon 50 or 100 µM liquiritigenin treatment, indicating that 
liquiritigenin induced a weak expression of HO-1 in OCLs (Fig. 4A). 
Finally, the effects of liquiritigenin on RANKL-induced early intracellular signaling 
pathways, including the phosphorylation of p38 MAPK, JNK, IκBα, Erk, and Akt were 
analyzed by western blotting, during the OCL differentiation of BMMs, since these 
signaling cascades are important for osteoclastogenesis (Boyle et al., 2003). BMMs 
were pre-incubated with 50 μM liquiritigenin for 24 h and subsequently stimulated with 
RANKL according to a previous protocol (Lee et al., 2010). Liquiritigenin slightly 
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inhibited the phosphorylation of Erk, JNK, and IκBα (Fig. 4B). However, the 
phosphorylation of p38 and Akt was enhanced after liquiritigenin. These results indicate 
that liquiritigenin inhibits some RANKL-induced signaling cascades such as Erk, JNK, 
and IκBα, but conversely increases p38 and Akt signaling. 
 
4. Discussion 
A previous study has reported that liquiritigenin induced enhanced cell growth, 
increased alkaline phosphatase activity, increased collagen synthesis, and the 
mineralization of osteoblastic MC3T3-E1 cells (Choi, 2012). However, the detailed 
mechanisms of the liquiritigenin-mediated proliferation of osteoblastic cells have not 
yet been determined. In this study, we found that the phosphorylation of Smad1/5 in 
liquiritigenin-treated MC3T3-E1 cells clearly increased compared to untreated cells. We 
further demonstrated that liquiritigenin inhibited osteoclast differentiation from BMMs 
and RAW-D cells into mature OCLs in vitro. Liquiritigenin markedly prevented the 
bone-resorption activity of OCLs. Upon liquiritigenin treatment, the phosphorylation of 
Erk, p38 MAPK, Akt, and JNK was abolished, and there were slight effects on 
IκBα-dependent pathways. Moreover, the expression of NFATc1 and its regulated 
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proteins such as Src and cathepsin K were down-regulated in OCLs. Thus, liquiritigenin 
has dual effects on the proliferation of bone cells, regarding the promotion of osteoblast 
differentiation and the inhibition of osteoclast differentiation. 
The effects of liquiritigenin on cell viability are most likely to be rather mild. The 
previous study reported that liquiritigenin increased cell growth, alkaline phosphatase 
activity, and collagen synthesis in osteoblastic MC3T3-E1 cells (Choi, 2012). 
Consistent with these results, this study also showed that liquiritigenin increased cell 
growth and alkaline phosphatase activity. Moreover, liquiritigenin caused significantly 
increased cell viability of RANKL-stimulated BMMs at higher concentrations (50 - 100 
µM), although it inhibited the cell viability of RANKL-stimulated RAW-D cells at the 
same concentrations. The detailed mechanisms behind the discrepancy between BMMs 
and RAW-D cells are presently unknown. Nevertheless, it is most likely that 
liquiritigenin has mild effects on the viability of bone cells, such as osteoblastic and 
osteoclastic cells. Therefore, this study raises the possibility that liquiritigenin may be a 
safe therapeutic agent for maintaining bone, including stimulation of bone formation, 
during late life. 
In addition to cell viability, liquiritigenin has been shown to significantly decrease 
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the production of OCL differentiation factors, such as tumor necrosis factor-α, 
interleukin-6, and receptor RANKL in osteoblastic MC3T3-E1 cells (Choi, 2012). 
Moreover, this study showed that liquiritigenin prevented the OCL differentiation and 
bone-resorption activity of OCLs (Choi, 2012). Thus, liquiritigenin has effects on 
decreasing bone resorption. 
Estrogen receptors are speculated to be target molecules of liquiritigenin in bone 
cells. Since liquiritigenin has been shown to selectively bind to estrogen receptor β, it is 
most likely that liquiritigenin works as a kind of “phytoestrogen” (Mersereau et al., 
2008). Phytoestrogens are plant-derived bioactive compounds that have structural and 
physiological effects similar to that of estradiol. Estrogen receptor α regulates the 
proliferative effects of estrogens in the target tissues, whereas estrogen receptor β has 
rather suppressive effects on estrogen receptor α (Jiang et al., 2013). Generally, 
phytoestrogens have dual effects on bone cells, such as the promotion of OBL 
maturation and the inhibition of OCL differentiation. For example, genistein, a 
representative soy isoflavone, has been shown to have effects on the enhancement of 
OBL differentiation (Chen et al., 2003) and the inhibition of OCL differentiation (Bitto 
et al., 2010). Since genistein prevents trabecular bone loss in ovariectomy mouse in vivo, 
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which is a model of osteoporosis (Wu et al., 2001), determining whether liquiritigenin 
can promote bone formation in vivo is of interest. 
During preparation of this study, Chen et al. have reported that several dietary 
phenolic acids stimulate OBL differentiation and proliferation, and it inhibits adipocyte 
differentiation in vitro, leading to increased bone mass in vivo (Chen et al., 2014). 
Considering these similarities, it will be of interest to determine whether liquiritigenin 
has inhibitory effects on adipocyte differentiation in vitro, resulting in increased bone 
mass in vivo. 
5. Conclusions 
This study determined that liquiritigenin promotes OBL differentiation of 
MC3T3-E1 cells via increased phosphorylation of Smad1/5. Conversely, liquiritigenin 
prevented OCL differentiation through multiple pathways, such as Erk, p38 MAPK, and 
JNK. These results indicate that liquiritigenin has dual effects on the proliferation of 
bone cells, regarding the promotion of OBL differentiation and the inhibition of OCL 
differentiation. Liquiritigenin may be considered an effective therapeutic and/or 
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Fig. 1. (A). The structure of liquiritigenin. (B, C) The effects of liquiritigenin on 
osteoblast differentiation of MC3T3-E1 cells. MC3T3-E1 cells were incubated with 
α-MEM containing 50 μg/mL ascorbic acid, 5 mM β-glycerolphosphate, and 1 μM 
dexamethasone for 7days (B), or 100 μM rhBMP-2 for 4days (C) in the absence or 
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presence of liquiritigenin (2.5, 5, 10, 25, 50 and 100 μM). After fixation, alkaline 
phosphatase staining was performed. (D) The effects of liquiritigenin on the signaling 
underlying osteoblast (OBL) differentiation. MC3T3-E1 cells were incubated with 100 
μM rhBMP-2 in the absence or presence of 50 μM liquiritigenin. Cell lysates with equal 
amounts of protein were subjected to SDS-PAGE, followed by western blotting with 
Abs to p-Smad1/5 or total Smad1/5. β-actin was used as a loading control. The data are 
representative of 3 independent experiments. 
 
Fig. 2. The effects of liquiritigenin on osteoclast (OCL) differentiation from RAW-D 
cells. (A) RAW-D cells were cultured for 72 h with the indicated concentrations of 
liquiritigenin in the presence of receptor activator of nuclear factor kappa-B ligand 
(RANKL; 50 ng/mL). TRAP staining was performed after fixation. The data are 
representative of 3 independent experiments. (B) The number of TRAP-positive 
multinucleated OCLs at 72 h of culture was counted. (C) Cell viability of the 
RAW-D-cell-derived-OCLs at 72 h of culture was analyzed using the Cell Counting Kit. 
The data shown in panels B and C are the mean ± SD of 3 independent experiments. 
The asterisks indicate statistical significance compared to the control cells without 
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liquiritigenin, ** P < 0.01. (D)The effects of liquiritigenin on osteoclast (OCL) 
differentiation from bone marrow-derived macrophages (BMMs). BMMs were cultured 
for 72 h with the indicated concentrations of liquiritigenin in the presence of 
macrophage colony stimulating factor (M-CSF; 30 ng/mL) and receptor activator of 
nuclear factor kappa-B ligand (RANKL; 50 ng/mL). TRAP staining was performed 
after fixation. The data are representative of 3 independent experiments. (E) The 
number of TRAP-positive multinucleated OCLs at 72 h of culture was counted. (F) Cell 
viability of the BMM-derived-OCLs at 72 h of culture was analyzed using the Cell 
Counting Kit. The data shown in panels E and F are the mean ± SD of 3 independent 
experiments. The asterisks indicate statistical significance compared to the control cells 
without liquiritigenin, * P < 0.05, ** P < 0.01. 
 
Fig. 3. The effects of liquiritigenin on the bone-resorption activity of osteoclasts (OCLs). 
Bone marrow-derived macrophages (BMMs) were cultured for 7 days in the presence of 
macrophage colony stimulating factor (M-CSF; 30 ng/mL) and receptor activator of 
nuclear factor kappa-B ligand (RANKL; 50 ng/mL). (A) Addition of liquiritigenin was 
performed under two different conditions; before differentiation (at the beginning time) 
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or after differentiation (at 3 days after differentiation). (B) Photographs of addition of 
liquiritigenin before differentiation (at the beginning time). The data are representative 
of 3 independent experiments. (C) Photographs of addition of liquiritigenin after 
differentiation (at 3 days after differentiation). The data are representative of 3 
independent experiments. 
 
Fig. 4. (A) The effects of liquiritigenin on the protein expression of osteoclast (OCL) 
marker proteins. Bone marrow-derived macrophages (BMMs) were cultured with 
macrophage colony stimulating factor (M-CSF; 30 ng/mL) and receptor activator of 
nuclear factor kappa-B ligand (RANKL; 50 ng/mL) for 60 h in the presence of 
liquiritigenin at the indicated concentrations (0, 2, 5, 10, 50, and 100 μM). The same 
protein amounts of cell lysates were subjected to SDS-PAGE, followed by western 
blotting with Abs specific to c-fms, RANK, NFATc1, Src, and cathepsin K. β-Actin was 
used as a loading control. The data are representative of 3 independent experiments. 
(B) The effects of liquiritigenin on the essential signaling of osteoclast (OCL) 
differentiation. Bone marrow-derived macrophages (BMMs) were cultured with 
macrophage colony stimulating factor (M-CSF; 30 ng/mL) for 24 h in the presence or 
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absence of 10 μM liquiritigenin. After 2 h of culture with serum-free media, the cells 
were subsequently stimulated with receptor activator of nuclear factor kappa-B ligand 
(RANKL; 300 ng/mL) for the indicated times (0, 5, 10, 15, and 30 min). Cell lysates 
with equal amounts of protein were subjected to SDS-PAGE, followed by western 
blotting with Abs to p-Erk, p-p38 MAPK, p-JNK, p-Akt, and p- IκBα. β-actin was used 
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